Skip to content

OptimizeRx OPRX Amortization Of Financing Costs

Amortization Of Financing Costs at other companies

Spectral AI, Inc. logo
Spectral AI, Inc.MDAI
$179K

Other financials

Income statement

See full
Revenue$19.8M-9.5%
Gross profit$14.9M+11.9%
Operating income$396.0K+119%
Net income-$495.0K+77.5%
EPS (diluted)-$0.03+75.0%

Balance sheet

See full
Cash & equivalents$20.2M+21.7%
Total debt$23.7M-27.7%
Total equity$129.6M+11.5%
Total assets$167.3M-0.3%

Cash flow

See full
Operating cash flow-$467.0K-112%
CapEx$21.0K-22.2%
Free cash flow-$488.0K-113%

Valuation

See full
Market cap$107.34M-54.1%
Enterprise value$110.88M-55.0%
P/E15.7×
P/S-1.2×

Profitability

See full
Gross margin70%+14.1pp
Operating margin13.2%
Net margin6.4%+3.6pp
FCF margin13.4%+4.8pp

Returns & leverage

See full
Return on equity5.6%+3.3pp
Debt / equity0.2×-0.1×
Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's amortization of financing costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OptimizeRx's amortization of financing costs?
OptimizeRx (OPRX) reported amortization of financing costs of $358K in Q1 2026.
How has OptimizeRx's amortization of financing costs changed year-over-year?
OptimizeRx's amortization of financing costs increased by 105.7% year-over-year, from $174K to $358K.
What is the long-term trend for OptimizeRx's amortization of financing costs?
Over 2 years (2023 to 2025), OptimizeRx's amortization of financing costs has grown at a 129.4% compound annual growth rate (CAGR), from $211K to $1.11M.